Ardelyx (ARDX) Receiving Somewhat Favorable Press Coverage, Study Shows

Media headlines about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0564127670545 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of equities research analysts recently weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $12.00 price objective (down previously from $13.00) on shares of Ardelyx in a report on Tuesday, November 28th. ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $12.00 price objective on shares of Ardelyx in a report on Tuesday, November 21st. Ladenburg Thalmann Financial Services decreased their price objective on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, November 22nd. Finally, Zacks Investment Research upgraded shares of Ardelyx from a “sell” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $12.64.

Ardelyx (NASDAQ:ARDX) traded up $0.15 during trading hours on Friday, hitting $6.10. 216,912 shares of the stock traded hands, compared to its average volume of 404,764. Ardelyx has a twelve month low of $4.05 and a twelve month high of $16.30.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.10. During the same quarter in the prior year, the business posted ($0.65) earnings per share. sell-side analysts expect that Ardelyx will post -2.01 earnings per share for the current year.

In other news, COO Reginald Seeto sold 10,008 shares of the business’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 15.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ardelyx (ARDX) Receiving Somewhat Favorable Press Coverage, Study Shows” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/12/09/ardelyx-ardx-receiving-somewhat-favorable-press-coverage-study-shows.html.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply